Friday, August 21, 2026
GlobeNewsInfo Logo
Home / Business & Corporate / Akebia Therapeutics secures USD 140 million debt facility with Symbiotic Capital to refinance obligations and extend operational runway

Akebia Therapeutics secures USD 140 million debt facility with Symbiotic Capital to refinance obligations and extend operational runway

Published on
Akebia Therapeutics secures USD 140 million debt facility with Symbiotic Capital to refinance obligations and extend operational runway
Image used for illustrative purposes only. GlobeNewsInfo / Visuals

Akebia Therapeutics has finalized a senior secured term loan facility of up to USD 140 million with Symbiotic Capital. The initial USD 60 million tranche refinances existing BlackRock debt, while an optional USD 80 million remains available, securing a two-year cash runway for the kidney disease-focused biopharmaceutical firm.

UNITED STATES OF AMERICA —Akebia Therapeutics has finalized a senior secured term loan arrangement valued at up to USD 140 million with Symbiotic Capital. The agreement includes an immediately funded initial tranche of USD 60 million, the proceeds of which were deployed to completely retire a prior USD 55 million credit facility held with BlackRock. The remaining USD 80 million is structured as a discretionary incremental tranche, subject to the lender’s future approval. The debt instrument carries a five-year maturity timeline, featuring an interest-only period for the first 60 months, with principal repayment due at term completion. The applicable interest rate is variable, set at the higher of the WSJ Prime rate plus 4.5 percent or a floor of 11.5 percent.

This financial restructuring is strategically significant for the biopharmaceutical sector, as it demonstrates a viable pathway for clinical-stage and commercial-stage companies to secure nondilutive capital amid restrictive equity markets. By replacing existing obligations with a longer-duration facility, the organization mitigates near-term liquidity risks and reaffirms its operational cash runway for a minimum of two years. This stability is critical for sustaining ongoing research and development initiatives without forcing unfavorable equity raises that would dilute existing shareholder value.

The transaction highlights evolving dynamics in healthcare credit markets, where specialized lending platforms are increasingly filling the financing gap left by traditional venture capital. Stakeholders across the nephrology and broader pharmaceutical industries will monitor this development as a benchmark for alternative debt structuring. It signals to institutional investors that revenue-generating biopharmaceutical firms with targeted therapeutic portfolios can access tailored credit solutions to bridge the capital-intensive gap between clinical development and broader market expansion.

Akebia Therapeutics is a Massachusetts-based biopharmaceutical organization established in 2007, specializing in the development and commercialization of therapies designed to improve outcomes for patients affected by kidney disease. Symbiotic Capital operates as a dedicated healthcare credit platform, leveraging extensive industry expertise to deliver structured lending solutions that fuel the growth of established medical enterprises on a global scale.

About GlobeNewsInfo

GlobeNewsInfo is a business news platform providing latest updates on global business developments, projects, and contract opportunities across diverse sectors and regions. The platform is designed to serve as a trusted source of information for companies, investors, and professionals worldwide.

More on Business & Corporate

Latest Business News

Share this Article

Just In
5 minutes ago Refex Industries secures INR 280 million contract for Pond Ash management 22 minutes ago Adani Wind advances renewable energy capabilities with manufacturing milestone in Gujarat 25 minutes ago Mercury EV-Tech targets Malawi transport sector with Lilongwe electric vehicle pact 43 minutes ago Molan Steel outlines Saudi manufacturing and distribution partnership with Turkish refrigeration supplier